First-Line Treatment with Encorafenib Plus Cetuximab Plus mFOLFOX6 Significantly Improves ORR in Patients with BRAF V600E-mutated mCRC By Ogkologos - February 17, 2025 461 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR FDA Approves Olutasidenib for Relapsed or Refractory Acute Myeloid Leukaemia with... December 9, 2022 Activity and Safety of Regorafenib Plus Nivolumab in First-Line Treatment for... February 22, 2024 Inhibition of GDF-15 with Ponsegromab Results in Increased Weight Gain and... September 20, 2024 The ecDNA story – catching the mastermind behind cancer evolution February 20, 2023 Load more HOT NEWS Por qué la Reunión Anual de la American Society of Clinical... Stress-Induced Immune Changes May Help Cancer Spread EMA Recommends Extension of Therapeutic Indications for Durvalumab to Patients with... Ovarian cancer screening trial did not save lives
